Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Investor Presentation (November 2019)
31 slides from Viyash Scientific's investor presentation, November 2019
Slide 1: Investor Presentation November 2019
Investor Presentation November 2019
Slide 2: Our Ambition: Leading Pure-play Animal Health Company
Our Ambition is to be a Leading Pure-play Animal Health Company in the world with integrated, end-to-end capabilities 2
Slide 3: Sequent Today
Sequent Today Largest Pureplay 8 Global Animal Health Company Manufacturing Assets 100+ from India into APIs, Formulations in India, Spain, Germany, Country Presence and analytical services Brazil and Turkey 26 $100 Mn Commercial Active 1,000+ Invested in R&D, manufacturing Pharmaceutical Ingredient
Slide 4: Advantageously placed in a growing opportunity
Advantageously placed in a growing opportunity USD Bn 27.0 Global animal heath industry will grow at a CAGR of 18.3 17.9 4.8% to reach US$ 45 billion by 2025 12.4 Production Animal with Production animal segment continue to have the Companion Animal larger share 2017 2025F SeQuent’s Focus Area Incre
Slide 5: Seeing the industry disruption at a distance
Seeing the industry disruption at a distance SeQuent in Early Days Rewired SeQuent ▪ Multiple business domains including animal health ▪ Price-sensitive, spot business ▪ Focus on building ▪ API-led strategy business around ▪ Volume driven Animal health domain ▪ Emerging markets footprint ▪ Unique, i
Slide 6: Strategic capacity building and differentiated products
SeQuent’s strategic capacity building, fast expanding market coverage and differentiated products driven by innovation enable us to outperform the industry 6
Slide 7: Global manufacturing presence
Global manufacturing presence Barcelona, Spain Warburg, Germany Tarapur, India Mahad, India AP P R O V AL S AP P R O V AL S AP P R O V AL S AP P R O V AL S EUGMP EUGMP cGMP EUGMP, COFEPRIS Vizag, India AP P R O V AL S USFDA, EUGMP, WHO Ambernath, India AP P R O V AL S India, Uganda, Ethiopia, Kenya
Slide 8: Production capabilities
Production capabilities FORMULATIONS API Barcelona Warburg Campinas Ankara Ambernath Vizag Mahad Tarapur Spain Germany Brazil Turkey India India India India Capabilities Dedicated Betalactam and - Dedicated Beta- Sterile granules 6 clean rooms 2 clean rooms 2 clean rooms betalactam hormones lactam b
Slide 9: Led by a global leadership team
Led by a global leadership team Corporate Head Manish Gupta Tushar Mistry Sharat Narasapur Managing Director Chief Financial Officer Technical Operations Business Head Allen Kelly Jose Nunes Filho Sirjiwan Singh Ashish Kakabalia United States LATAM Technical Operations - Europe Business Development
Slide 10: Broad-based portfolio providing differentiated solutions
Broad-based portfolio providing differentiated solutions Strong, diversified product base that World’s largest veterinary API addresses the needs of a multitude producer from India species within the formulation front Revenue FY19 ₹10,393 Mn Animal health Formulations Animal health API ($150 Mn) ₹7,
Slide 11: API: Competitive Edge in Animal Health
API: Competitive Edge in Animal Health 11
Slide 12: APIs: Scaling the capability curve
APIs: Scaling the capability curve Revenues in ₹ Mn 26 18 11 Commercial US Filings / CEP 3,248 APIs Approvals Filings 1,965 2,188 14+ 1.9x ~₹1 Bn Pipeline Asset Quarterly Turnover Run-rate FY19 Growth Highlights ▪ Deepening relationships with global top 10 veterinary companies is paying FY17 FY18 FY
Slide 13: Driven by top-5 customers
Driven by top-5 customers Growth FY19 vs. % Contribution of Customer FY18 sales Customer 1 2.0x 11% 2.4x Growth with Top-5 customers Customer 2 2.3x 8% Customer 3 2.7x 7% Customer 4 5.0x 5% 54% Contribution of Top 10 customers to API sales Customer 5 1.9x 5% 13
Slide 14: Alivira amongst 'Top 3' US FDA VMF Filers
Alivira amongst ‘Top 3’ US FDA VMF Filers Alivira is the # 1 Generic Animal Health USVMF Filer and # 3 Global Animal Health USVMF filer Strategic product selection US Veterinary Master File USFDA 2019, 3rd Quarter update API Filings Competition In last 3 years, Alivira has filed 17 APIs 5 Alivira on
Slide 15: Reaping benefits of well-executed strategy
Reaping benefits of well-executed strategy 2019 & BEYOND 2016 – 2018 TILL 2016 Securing high profits Building capability Establishing base ▪ Globally, first dedicated API facility in ▪ Regulated markets will continue to Vizag to get USFDA ▪ EHS-driven decision had led to contribute to growth ▪ Throu
Slide 16: Formulations: The Value Driver
Formulations: The Value Driver 16
Slide 17: Formulations: Value creation
Formulations: Value creation Revenues in ₹ Mn 35+ 80+ 50%+ Products Under Countries with Sales to regulated 7,145 Development marketing presence markets 6,306 4,925 1000+ 12 35+ Products focused on Dosage Forms Launches in Production Animals FY19 FY19 Growth Highlights ▪ Robust growth across geograp
Slide 18: Diversified offerings addressing the widespread needs
Diversified offerings addressing the widespread needs Revenue by Revenue by Revenue by Revenue by Region Species Therapy Dosage Form 14% 6%1% 10% 7% 4% 10% 5% 30% 13% 39% 40% 12% 26% 15% 51% 22% 12% 10% 32% 12% 29% Europe Multispecies Antibiotic Non-Injectables Powder / Premixes Emerging Markets Rum
Slide 19: Carving a niche in major global markets
Carving a niche in major global markets Alivira Direct Coverage Distributors Expansion plan Presence across 80 countries Direct Alivira marketing in 10 of Top 25 EU countries 19
Slide 20: Market coverage in 80+ countries: Europe and Turkey
Market coverage with deepening presence in 80+ countries Market Statistics SeQuent Presence Future Strategy Largest animal health Front-end team members in 7 ▪ Leverage Alivira’s strong brand 2nd market in the world 35+ of the top 10 EU countries (ES, image NL, BE, SE, DE, IT and FR) ▪ Establish fro
Slide 21: Market coverage in 80+ countries: Latin America
Market coverage with deepening presence in 80+ countries Market Statistics SeQuent Presence Future Strategy Dominated by Brazil and Mexico 25+ Registered Products ▪ Launch therapeutic products in BRAZIL nutritional additives and Of the global animal health 11+ Feld force supplements 6.7% business ac
Slide 22: Market coverage in 80+ countries: Emerging markets
Market coverage with deepening presence in 80+ countries Market Statistics SeQuent Presence Future Strategy ▪ Africa ▪ Establish front end presence in 9 key countries, 80+ approved parts of East Africa and Southeast Of the global animal health products, 14 field force Asia 1/4th business is represent
Slide 23: Calibrating with the growth strategy
Calibrating with the growth strategy 2020 & BEYOND 2017 – 2020 TILL 2017 Driving growth Building capacity Establishing the base ▪ Presence in 17 of Top 25 Animal ▪ New product launches and improved Health (AH) Markets with strong market share will drive the growth across ▪ Launched in India through
Slide 24: R&D to drive value creation in FDF business
R&D to drive value creation in FDF business Pipe Line of 35+ products 60% First Generics Niche Innovation Patent expiry 2 19 14 1/3rd US Only Global EU Only of our products ~1/2 Products Products Products leverage our API- of our portfolio Integrated made up of Approach Injectables Portfolio of 35+
Slide 25: Financials
Sequent S Proven Ability In Life Scie Financials
Slide 26: Relentless Execution
Relentless Execution 12,000 1,500 All values in ₹ Mn Revenue Contribution 23% CAGR 9,000 1,000 API FDF 31% 69% 6,000 500 Growth Highlights 3,000 - ▪ Fully integrated global animal health company from India with an annual run rate of $150 Mn ▪ Business Scaled 4.5X in four years - -500 ▪ Profitability
Slide 27: Continuing Growth Momentum
Continuing Growth Momentum All values in ₹ “ Mn H1 FY2020 YOY The first half of FY19 was very significant in our strategic journey as we completed EU filing of world’s largest animal injectable product. Our new, state-of –art H1 FY20 5,622 R&D facility is now functional at Ambernath in Mumbai as Rev
Slide 28: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn ROCE Net Debt to EBITDA Particulars Mar-19 6.35 13.0% 11.8% Shareholders' funds 7,067 7.8% 3.50 4.0% 1.84 1.79 Net Borrowings 2,447 FY17 FY18 FY19 H1 FY20* FY17 FY18 FY19 H1 FY20* Investments 1,797 *H1 Annualised Highlights Assets 5,208 ▪ ROCE jumped 800 bp
Slide 29: Future Outlook
Sequent & >) Proven Ability In Life Sciences ativira Future Outlook
Slide 30: Developing Skill & Scale to be a reputed Global Animal Health Company
Developing Skill & Scale to be a reputed Global Animal Health Company Consolidate Focus on New Strengthen Market Products/ Customer Presence Segments Centricity • Expand presence in • Pipeline of 14 • Established Top 10 EU markets complex APIs customer-centric, Building blocks global front-end for •
Slide 31: Thank You
Thank You SeQuent Scientific Limited CIN: L99999MH1985PLC036685, Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. £7, Road No. 22,Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra Tol No: +91 22 4111 4777 | Website: www.sequent.in | E-mail id: infogsequent.in
SeQuent Scientific — Investor Presentation (November 2019) on 6ix